A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 75,100 shares of AQST stock, worth $344,709. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,100
Previous 61,400 22.31%
Holding current value
$344,709
Previous $159,000 134.59%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.4 - $5.09 $1.69 Million - $3.58 Million
704,020 Added 419.53%
871,833 $4.34 Million
Q2 2024

Aug 14, 2024

SELL
$2.31 - $4.5 $130,422 - $254,070
-56,460 Reduced 25.17%
167,813 $436,000
Q1 2024

May 15, 2024

BUY
$2.01 - $6.09 $113,476 - $343,817
56,456 Added 33.64%
224,273 $955,000
Q4 2023

Feb 14, 2024

BUY
$1.29 - $2.47 $212,994 - $407,826
165,112 Added 6103.96%
167,817 $338,000
Q3 2023

Nov 14, 2023

SELL
$1.5 - $2.24 $873 - $1,303
-582 Reduced 17.71%
2,705 $4,000
Q2 2023

Aug 14, 2023

BUY
$1.06 - $2.49 $3,484 - $8,184
3,287 New
3,287 $5,000
Q4 2022

Feb 14, 2023

SELL
$0.77 - $1.18 $11,667 - $17,880
-15,153 Reduced 83.89%
2,910 $2,000
Q3 2022

Nov 14, 2022

SELL
$0.63 - $1.73 $33,977 - $93,302
-53,932 Reduced 74.91%
18,063 $21,000
Q2 2022

Aug 15, 2022

BUY
$0.64 - $2.57 $22,531 - $90,476
35,205 Added 95.69%
71,995 $46,000
Q1 2022

May 16, 2022

SELL
$2.28 - $4.26 $139,257 - $260,192
-61,078 Reduced 62.41%
36,790 $96,000
Q4 2021

Feb 14, 2022

BUY
$3.69 - $6.37 $207,219 - $357,720
56,157 Added 134.63%
97,868 $380,000
Q3 2021

Nov 15, 2021

SELL
$3.25 - $4.66 $109,694 - $157,284
-33,752 Reduced 44.73%
41,711 $182,000
Q1 2021

May 17, 2021

BUY
$4.17 - $6.73 $213,541 - $344,636
51,209 Added 211.14%
75,463 $392,000
Q4 2020

Feb 16, 2021

SELL
$4.65 - $7.79 $147,581 - $247,239
-31,738 Reduced 56.68%
24,254 $130,000
Q3 2020

Nov 16, 2020

BUY
$4.12 - $9.09 $122,631 - $270,563
29,765 Added 113.49%
55,992 $272,000
Q2 2020

Aug 14, 2020

BUY
$1.84 - $6.44 $28,713 - $100,496
15,605 Added 146.91%
26,227 $127,000
Q1 2020

May 15, 2020

SELL
$1.54 - $6.75 $23,343 - $102,316
-15,158 Reduced 58.8%
10,622 $23,000
Q3 2018

Nov 13, 2018

BUY
$15.0 - $18.96 $386,700 - $488,788
25,780 New
25,780 $0

Others Institutions Holding AQST

About Aquestive Therapeutics, Inc.


  • Ticker AQST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,350,700
  • Market Cap $245M
  • Description
  • Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...
More about AQST
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.